LONDON--(BUSINESS WIRE)--CooperGenomics, a CooperSurgical company which includes Reprogenetics, Recombine, and Genesis Genetics, is pleased to announce the receipt of ISO 15189 accreditation for both its London and Nottingham-based laboratories. Issued by the United Kingdom Accreditation Services (UKAS), this certification validates the quality and accuracy of the genetic testing services provided by the laboratories.
The accreditation includes all noninvasive prenatal testing (NIPT), preimplantation genetic diagnosis (PGD), and preimplantation genetic screening (PGS) services provided in the CooperGenomics London and Nottingham facilities. CooperGenomics is the first laboratory in the United Kingdom to receive such accreditation for NIPT and PGS services.
“We are honoured to have received this accreditation from UKAS,” said Tony Gordon, PhD, Vice President of Business Development at CooperGenomics in the UK. “As a leader in the field of reproductive genetic testing, we pride ourselves on the quality of our services, to which this certification is a testament.”
For more than 25 years, CooperSurgical has been a leader in manufacturing and marketing a wide range of trusted and innovative brands that have assisted clinicians in advancing the standard of health care for women worldwide. Through an aggressive growth and diversification strategy, CooperSurgical has evolved its portfolio to include key products and services for women’s health, fertility and genetic testing. Our global in vitro fertilization (IVF) segment, ORIGIO, and our groundbreaking offering from the pioneers of genetic testing, Recombine/Reprogenetics/Genesis Genetics, complement our dynamic women’s health care offering.
CooperSurgical, Inc. is a wholly owned subsidiary of The Cooper Companies (NYSE: COO) and is headquartered in Trumbull, CT. Through the delivery of insightful technologies and products to health care providers, we envision a world with healthier babies, individuals, and families. More information can be found at www.coopersurgical.com.